Peer-reviewed veterinary case report
Radiation therapy improves nasal tumors in 29 dogs with few side
By Gieger, T L & Nolan, M W·Published in Veterinary and comparative oncology·2018·Department of Clinical Sciences and Comparative Medicine Institute·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Linac-based stereotactic radiation therapy for canine non-lymphomatous nasal tumours: 29 cases (2013-2016).
- Species:
- dog
Plain-English summary
Twenty-nine dogs with non-lymphomatous nasal tumors were treated with a specialized radiation therapy called stereotactic radiation therapy (SRT). After treatment, all dogs showed improvement in their symptoms, and follow-up scans revealed that most had either partial or complete responses to the therapy. While some dogs experienced minor side effects, such as oronasal fistulas, the overall treatment was well tolerated. On average, dogs lived about 586 days after treatment, with many remaining tumor-free for over a year. This therapy seems to provide a good option for dogs with these types of tumors.
People also search for: dog nasal tumor treatment · stereotactic radiation therapy for dogs · canine nasal cancer survival rate
Abstract
Twenty-nine dogs were treated with linac-based stereotactic radiation therapy (SRT) for non-lymphomatous nasal tumours. Only dogs with a follow-up time >365 days were included in this retrospective analysis. No dogs had evidence of distant metastasis at diagnosis. Treatment was planned and a total of 30 Gy in 3 daily 10 Gy fractions was delivered using intensity-modulation, cone-beam CT-based image guidance and a robotic treatment couch. Clinical signs improved in all cases. Nineteen dogs had CT scans 3-4 months post-SRT and all had partial or complete tumour response. Minimal acute toxicities were detected. Clinically significant late toxicities included oronasal or nasocutaneous fistulas (N = 3) and biopsy-confirmed fungal rhinitis with no evidence of tumour progression (N = 2). The median progression-free survival (PFS) was 354 days, with 49% and 39% progression-free at 1 and 2 years post-SRT, respectively. The median survival time (ST) was 586 days, with 69% and 22% alive 1 and 2 years post-SRT, respectively. Neither the clinical parameters evaluated (modified Adams' stage, histopathology, presence of intracranial extension of the tumour) nor dosimetric data were predictive for PFS or ST. This SRT protocol appears to be well tolerated, and PFI and ST are comparable or superior to those reported in other definitive-intent radiotherapy protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28741887/